• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

ASA: Stem Cell Transplant Improves Vasculopathy in Sickle Cell Patients
THURSDAY, Feb. 9, 2023 -- For adults with sickle cell disease (SCD), hematopoietic stem cell transplantation (HSCT) seems to improve or prevent development of vasculopathies, according to a study presented at the American Stroke Association...
Source: Drugs.com - Pharma News - February 9, 2023 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Perioperative Stroke Examined in Children Receiving Heart Transplants
WEDNESDAY, July 13, 2022 -- Among children receiving a cardiac transplant, Black children have a lower incidence of perioperative stroke, but their long-term mortality rate following stroke is higher compared with White children, according to a...
Source: Drugs.com - Pharma News - July 13, 2022 Category: Pharmaceuticals Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

First baby born after uterus transplant from deceased donor
The first baby gestated in a uterus transplanted from a cadaver has been born in Brazil, according to a case reported in the medical journal The Lancet. The 32-year-old mother, who was born without a uterus, underwent a 10-hour transplant surgery in 2016 then underwent fertility treatment, the BBC reported. The donor was a woman in her 40s who died from a stroke. The mother’s eggs were removed from her ovaries, fertilized with the father’s sperm, then implanted in the donor urerus after the…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 5, 2018 Category: Pharmaceuticals Authors: Anne Stych Source Type: news